Source-grounded facts extracted from BICYCLE THERAPEUTICS PLC's SEC 8-K filings across all families, newest first. Each cites a verbatim SEC excerpt.
BICYCLE THERAPEUTICS PLC reported financial results for the fiscal quarter ended March 31, 2026.
“On April 30, 2026, Bicycle Therapeutics plc issued a press release announcing financial results for the fiscal quarter ended March 31, 2026 and other business highlights.”
Santiago Arroyo resigned as Chief Development Officer at BICYCLE THERAPEUTICS PLC.
“Santiago Arroyo, M.D., Ph.D., notified the Board of his resignation as the Company's Chief Development Officer, effective March 24, 2025.”
Richard Kender resigned as Director at BICYCLE THERAPEUTICS PLC.
“On March 27, 2025, the Company also announced that Pierre Legault, MBA, CPA, and Richard Kender, MBA, would not be standing for re-election at the 2025 Annual Meeting, and that each of Mr. Legault and Mr. Kender would retire from the Board effective immediately following the 2025 Annual Meeting.”
Pierre Legault resigned as Director at BICYCLE THERAPEUTICS PLC.
“On March 27, 2025, the Company also announced that Pierre Legault, MBA, CPA, and Richard Kender, MBA, would not be standing for re-election at the 2025 Annual Meeting, and that each of Mr. Legault and Mr. Kender would retire from the Board effective immediately following the 2025 Annual Meeting.”
Alessandro Riva was appointed as Director at BICYCLE THERAPEUTICS PLC.
“appointed Alessandro Riva, M.D., to the Board and the Scientific Committee of the Board, effective as of the close of business on March 25, 2025, New York City time.”
BICYCLE THERAPEUTICS PLC shareholders approved To adopt the new articles of association in substitution for, and to the exclusion of, the Company's existing articles of association. at the 2024-05-16 meeting.
“Proposal 11 – To adopt the new articles of association in substitution for, and to the exclusion of, the Company’s existing articles of association. For Against Vote Withheld/Abstain 37,371,711 15,138 11,258”
BICYCLE THERAPEUTICS PLC shareholders approved To authorize the Board to allot equity securities for cash up to a maximum aggregate nominal amount of £1,000,000 pursuant to the authorization in Resolution 9 as if U.K. statutory pre-emption rights did not apply. at the 2024-05-16 meeting.
“Proposal 10 – To authorize the Board to allot equity securities for cash up to a maximum aggregate nominal amount of £1,000,000 pursuant to the authorization in Resolution 9 as if U.K. statutory pre-emption rights did not apply. For Against Vote Withheld/Abstain 32,350,797 4,154,715 892,595”
BICYCLE THERAPEUTICS PLC shareholders approved To authorize the Board to allot shares in the Company or to grant rights to subscribe for or to convert any security into shares in the Company up to a maximum aggregate nominal amount of £1,000,000. at the 2024-05-16 meeting.
“Proposal 9 – To authorize the Board to allot shares in the Company or to grant rights to subscribe for or to convert any security into shares in the Company up to a maximum aggregate nominal amount of £1,000,000. For Against Vote Withheld/Abstain 33,241,556 4,146,578 9,973”
BICYCLE THERAPEUTICS PLC shareholders approved To approve the directors' remuneration report for the year ended December 31, 2023. at the 2024-05-16 meeting.
“Proposal 8 – To approve the directors’ remuneration report for the year ended December 31, 2023. For Against Vote Withheld/Abstain 36,200,790 1,188,057 9,260”
BICYCLE THERAPEUTICS PLC shareholders approved To receive and adopt the Company's U.K. statutory annual accounts and reports for the year ended December 31, 2023. at the 2024-05-16 meeting.
“Proposal 7 – To receive and adopt the Company’s U.K. statutory annual accounts and reports for the year ended December 31, 2023. For Against Vote Withheld/Abstain 36,494,043 896,166 7,898”
BICYCLE THERAPEUTICS PLC shareholders approved To authorize the Audit Committee of the Company's Board of Directors to determine the Company's U.K. statutory auditors' remuneration for the year ending December 31, 2024. at the 2024-05-16 meeting.
“Proposal 6 – To authorize the Audit Committee of the Company’s Board of Directors (the “Board”) to determine the Company’s U.K. statutory auditors’ remuneration for the year ending December 31, 2024. For Against Vote Withheld/Abstain 37,376,455 14,150 7,502”
BICYCLE THERAPEUTICS PLC shareholders approved To re-appoint PricewaterhouseCoopers LLP, a limited liability partnership organized under the laws of England, as the Company's U.K. statutory auditors, to hold office until the conclusion of the next annual general meeting of shareholders. at the 2024-05-16 meeting.
“Proposal 5 – To re-appoint PricewaterhouseCoopers LLP, a limited liability partnership organized under the laws of England, as the Company’s U.K. statutory auditors, to hold office until the conclusion of the next annual general meeting of shareholders. For Against Vote Withheld/Abstain 37,376,531 14,071 7,505”
BICYCLE THERAPEUTICS PLC shareholders approved To ratify the appointment of PricewaterhouseCoopers LLP, a limited liability partnership organized under the laws of England, as the Company's U.S. independent registered public accounting firm for the year ending December 31, 2024. at the 2024-05-16 meeting.
“Proposal 4 – To ratify the appointment of PricewaterhouseCoopers LLP, a limited liability partnership organized under the laws of England, as the Company’s U.S. independent registered public accounting firm for the year ending December 31, 2024. For Against Vote Withheld/Abstain 37,376,526 14,076 7,505”
BICYCLE THERAPEUTICS PLC shareholders approved To approve, on an advisory basis, the compensation of the Company's named executive officers, as disclosed in the Company's definitive proxy statement. at the 2024-05-16 meeting.
“Proposal 3 – To approve, on an advisory basis, the compensation of the Company’s named executive officers, as disclosed in the Company’s definitive proxy statement. For Against Vote Withheld/Abstain 36,186,115 1,202,477 9,515”
BICYCLE THERAPEUTICS PLC shareholders approved To re-elect as a director Jose-Carlos Gutierrez-Ramos. at the 2024-05-16 meeting.
“Proposal 2 – To re-elect as a director Jose-Carlos Gutierrez-Ramos. For Against Vote Withheld/Abstain 35,019,069 2,371,385 7,653”
BICYCLE THERAPEUTICS PLC shareholders approved To re-elect as a director Kevin Lee. at the 2024-05-16 meeting.
“Proposal 1 – To re-elect as a director Kevin Lee. For Against Vote Withheld/Abstain 36,413,260 977,286 7,561”
BICYCLE THERAPEUTICS PLC reported first quarter ended March 31, 2024 results: net income Net loss was $26.6 million, EPS $(0.62) basic and diluted net loss per share.
“Net loss was $26.6 million, or $(0.62) basic and diluted net loss per share, for the three months ended March 31, 2024”
Facts are extracted by an LLM and gated to those whose source quote is present verbatim in the filing text. Coverage is best-effort while backfill and monitoring mature; this is not yet a full-market index. See methodology.